Ipsen says to seek approval for muscle-spasm drug
PARIS (Reuters) - French drugmaker Ipsen said that it would begin the process of regulatory approval for a muscle-spasm drug, branded Dysport Next Generation, after a liquid-toxin trial showed it was "safe and efficacious".
"On the basis of these results and feedback from the principal investigator of the Phase III study, Ipsen intends to initiate a dialogue with key agencies on the regulatory approach to file the first ready-to-use liquid toxin A in Europe and rest-of-world," Ipsen said.
(Reporting by Lionel Laurent)
- Qatar adamant it will host 2022 World Cup despite doubts
- Argentina's Fernandez to meet billionaire investor Soros in New York
- New Jersey hiker killed by black bear : police
- Islamic State urges attacks on U.S., French citizens, taunts Obama
- Housing data hits Wall Street; S&P has worst day since August 5